Cellectis reports Q2 2026 results as lasme-cel gains FDA RMAT status
Cellectis said its pivotal Phase 2 BALLI-01 trial is advancing with FDA RMAT designation and $169 million in cash to fund operations into Q4 2027.
SEC filing
Latest
1 story
Sign inSign in1 story
Cellectis said its pivotal Phase 2 BALLI-01 trial is advancing with FDA RMAT designation and $169 million in cash to fund operations into Q4 2027.
SEC filing